Accès gratuit
Numéro
Med Sci (Paris)
Volume 30, Numéro 6-7, Juin–Juillet 2014
Page(s) 608 - 610
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20143006003
Publié en ligne 11 juillet 2014
  1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the american heart association. Circulation 2014 ; 129 : e28–e292. [CrossRef] [PubMed] [Google Scholar]
  2. Lackland DT, Roccella EJ, Deutsch AF, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke 2014 ; 45 : 315–353. [CrossRef] [PubMed] [Google Scholar]
  3. Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976 ; 7 : 135–142. [CrossRef] [PubMed] [Google Scholar]
  4. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995 ; 333 : 1581–1587. [CrossRef] [PubMed] [Google Scholar]
  5. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013 ; 44 : 870–947. [CrossRef] [PubMed] [Google Scholar]
  6. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008 ; 372 : 1303–1309. [CrossRef] [PubMed] [Google Scholar]
  7. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008 ; 359 : 1317–1329. [CrossRef] [PubMed] [Google Scholar]
  8. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007 ; 369 : 275–282. [CrossRef] [PubMed] [Google Scholar]
  9. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013 ; 368 : 893–903. [CrossRef] [PubMed] [Google Scholar]
  10. Galaup A, Gomez E, Souktani R, et al. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation 2012 ; 125 : 140–149. [CrossRef] [PubMed] [Google Scholar]
  11. Bouleti C, Mathivet T, Coqueran B, et al. Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke. Eur Heart J 2013 ; 34 : 3657–3668. [CrossRef] [PubMed] [Google Scholar]
  12. Le Jan S, Amy C, Cazes A, et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003 ; 162 : 1521–1528. [CrossRef] [PubMed] [Google Scholar]
  13. Galaup A, Cazes A, Le Jan S, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA 2006 ; 103 : 18721–18726. [CrossRef] [Google Scholar]
  14. Padua D, Zhang XH, Wang Q, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008 ; 133 : 66–77. [CrossRef] [PubMed] [Google Scholar]
  15. Cazes A, Galaup A, Chomel C, et al. Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton. Circ Res 2006 ; 99 : 1207–1215. [CrossRef] [PubMed] [Google Scholar]
  16. Chomel C, Cazes A, Faye C, et al. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity. Faseb J 2009 ; 23 : 940–949. [CrossRef] [PubMed] [Google Scholar]
  17. Zhu P, Goh YY, Chin HF, et al. Angiopoietin-like 4: a decade of research. Bioscience reports 2012 ; 32 : 211–219. [CrossRef] [PubMed] [Google Scholar]
  18. Galaup A, Germain S. Protèger l’intégrité du réseau vasculaire coronaire. Med Sci (Paris) 2012 ; 28 : 133–135. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  19. Sukonina V, Lookene A, Olivecrona T, Olivecrona G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc Natl Acad Sci USA 2006 ; 103 : 17450–17455. [CrossRef] [Google Scholar]
  20. Lafferty MJ, Bradford KC, Erie DA, Neher SB. Angiopoietin-like protein 4 inhibition of lipoprotein lipase: evidence for reversible complex formation. J Biol Chem 2013 ; 288 : 28524–28534. [CrossRef] [PubMed] [Google Scholar]
  21. Eltzschig HK, Eckle T. Ischemia and reperfusion: from mechanism to translation. Nat Med 2011 ; 17 : 1391–1401. [CrossRef] [PubMed] [Google Scholar]
  22. Leys D, Cordonnier C. Traitements des accidents vasculaires cérébraux en phase aiguë et prévention secondaire. Med Sci (Paris) 2009 ; 25 : 733–738. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  23. Bordet R, Ouk T, Onténiente B, et al. Ischémie cérébrale. Les pistes thérapeutiques de demain. Med Sci (Paris) 2009 ; 25 : 847–854. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  24. Macé C, Clément LC. Implication d’Angptl4 dans le syndrome néphrotique : une protéine à deux visages. Med Sci (Paris) 2014 ; 30 : 605–607. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.